抗磷脂抗体对系统性红斑狼疮妊娠结局的预后价值
基于中国单中心SLE队列441例单胎妊娠的分析显示,aPLs阳性者发生不良妊娠结局的风险显著升高(OR 2.56,95%CI 1.38-4.65),LA联合aCL和/或抗β2GPI的IgG型为最高风险组合(OR 3.98,95%CI 1.66-9.35),提示SLE妊娠需按aPL谱分层管理。
要点
- SLE妊娠中aPLs阳性者APOs发生率明显高于阴性者(29.5% vs 13.2%)。
- LA联合aCL和/或抗β2GPI的IgG型是APOs最高风险组合(OR 3.98)。
- aCL IgM和抗β2GPI IgM未显著增加APOs风险,需区分aPL亚型。
核心结论
- aPLs与SLE患者不良妊娠结局风险升高相关,不同aPL谱对妊娠结局影响不同。
- LA联合aCL和/或抗β2GPI的IgG型是APOs最高风险组合。
研究设计与样本
- 本研究分析中国单中心SLE队列数据,纳入441例单胎妊娠(来自410例SLE患者)。
- 检测aPL谱包括aCL IgG/IgM、抗β2GPI IgG/IgM和LA。
主要发现
- aPLs阳性者APOs发生率为29.5%,阴性者为13.2%,OR 2.56(95%CI 1.38-4.65,p=0.002)。
- aPLs与胎儿死亡风险升高相关(OR 3.87,95%CI 1.17-12.19,p=0.021),与活产失败风险升高相关(OR 2.54,95%CI 1.22-5.15,p=0.011)。
- aCL IgG(OR 3.02,95%CI 1.44-6.15,p=0.003)、抗β2GPI IgG(OR 2.60,95%CI 1.13-5.72,p=0.020)和LA(OR 2.85,95%CI 1.44-5.56,p=0.002)显著增加APOs风险,而aCL IgM和抗β2GPI IgM未显著增加。
- LA联合aCL和/或抗β2GPI的IgG型增加APOs风险(OR 3.98,95%CI 1.66-9.35,p=0.002),其他aPLs阳性组合未显著增加(OR 1.82,95%CI 0.81-3.81,p=0.128)。
关键数值与推荐
- APOs定义为胎儿死亡前、胎儿死亡、34周前发生重度子痫前期及34周前发生重度胎盘功能不全。
临床怎么用
- SLE妊娠管理应进行aPL风险分层,重点关注aPLs阳性者,尤其是LA联合aCL和/或抗β2GPI的IgG型阳性患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic lupus erythematosus (SLE) predominantly affects women of childbearing age and is often associated with adverse pregnancy outcomes (APOs). Antiphospholipid antibodies (aPLs) are known risk factors for APOs in the general population, and the prevalence of aPLs is higher in patients with SLE than healthy women. OBJECTIVE: This study aimed to investigate the impacts of aPLs and different aPLs profiles on pregnancy outcomes in patients with SLE. STUDY DESIGN: This study analysed data from a single-centre SLE cohort in China. aPLs profiles, including anticardiolipin antibodies (aCL) IgG/IgM, anti-β2 glycoprotein I (anti-β2GPI) antibodies IgG/IgM and lupus anticoagulant (LA), were measured. APOs were defined as prefetal death, fetal death, pre-eclampsia with severe features occurring before 34 weeks of gestation and placental insufficiency with severe features occurring before 34 weeks of gestation. RESULTS: The study comprised 441 singleton pregnancies occurring in 410 patients with SLE and 78 (17.9%) were positive for aPLs. Seventy-one (16.1%) patients developed APOs and 391 (88.7%) patients succeeded in giving a live birth. Patients with positive aPLs experienced APOs more frequently (29.5% vs 13.2%), with an OR of 2.56 (95% CI 1.38 to 4.65, p=0.002). aPLs were also associated with higher risks of fetal death (OR 3.87, 95% CI 1.17 to 12.19, p=0.021) and failure of live birth (OR 2.54, 95% CI 1.22 to 5.15, p=0.011). Analysis on the aPLs profiles revealed that aCL IgG (OR 3.02, 95% CI 1.44 to 6.15, p=0.003), anti-β2GPI IgG antibodies (OR 2.60, 95% CI 1.13 to 5.72, p=0.020) and LA (OR 2.85, 95% CI 1.44 to 5.56, p=0.002) increased the risks of APOs significantly, but aCL IgM and anti-β2GPI IgM antibodies did not. Further analysis demonstrated that LA plus IgG isotypes of aCL and/or anti-β2GPI antibodies was the highest-risk profile, increasing the incidences of APOs with an OR of 3.98 (95% CI 1.66 to 9.35, p=0.002), while the other combinations of aPLs positivity did not (OR 1.82, 95% CI 0.81 to 3.81, p=0.128). CONCLUSION: This study demonstrated the adverse effects of aPLs in patients with SLE regarding the pregnancy outcomes, and different aPLs profiles displayed distinct impacts. This highlights the importance of risk stratification when managing pregnancy among patients with SLE, putting more focus on those with positive aPLs, especially those positive for LA plus IgG isotypes of aCL and/or anti-β2GPI antibodies.
引用
- Zhang X, Huang C, Liu L, et al. Prognostic value of antiphospholipid antibodies in pregnancy outcomes in systemic lupus erythematosus. RMD Open. 2026. PMID: 42532548. doi:10.1136/rmdopen-2026-006870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。